Lupin shares gain on MEK Inhibitor agreement

Lupin and Boehringer lngelheim have entered into licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794).

MEK inhibitor compound (LNP3794) could be a potential targeted therapy for patients with difficult-to-treat cancers. The said partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

Lupin is an innovation-led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The shares of Lupin on Wednesday opened at Rs. 735.05 against Tuesday’s close of Rs. 735.20 on BSE. At closing hours, it was trading at Rs. 741.50, flat at 0.86 per cent from its previous close. The stock hit an intraday high of Rs. 744 and intraday low was Rs. 728. Its 52-week high was Rs. 764.00 and 52-week low was Rs. 711.60 per share on the BSE.